2016 News Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
01/27/16Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Jan. 27, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: 18th Annual BIO CEO & Investor Conference on Tuesday, February 9 at 8:00 a.m. ET at the Waldorf Astoria Hotel in New York City Leerink Partners 5th Annual Global Healthcare Conferen... 
Printer Friendly Version
01/21/16Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016
BOSTON--(BUSINESS WIRE)--Jan. 21, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at Immunotherapy World 2016 being held January 25-27, 2016 in Washington, DC. “Over the past couple of years, exciting data have emerged from several research groups demonstrating the importance of FAK inhibition in the i... 
Printer Friendly Version
01/06/16Washington University in St. Louis Initiates Clinical Study of Verastem’s VS-6063 in Combination with Merck’s Pembrolizumab and Gemcitabine in Pancreatic Cancer
BOSTON--(BUSINESS WIRE)--Jan. 6, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the initiation of a Phase 1 dose-escalation study at Washington University to evaluate Verastem’s FAK inhibitor VS-6063 in combination with Merck’s PD-1 inhibitor pembrolizumab and gemcitabine in patients with pancreatic cancer. This is the first of several combination clinical trials the Company expects ... 
Printer Friendly Version